Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Pharma & Drugs
Share your love
Global trial equity: How LMIC data is reshaping US ophthalmology research | Ophthalmology Times
Incorporating data from low- and middle-income countries may help redefine how ophthalmology trials are designed, evaluated, and applied in practice (Image credit: AdobeStock/PUTRABATARA) Innovation in ophthalmology is often measured by what reaches the clinic—but the path to those breakthroughs begins…
Comparing Aflibercept 8 mg and Faricimab in RVO | Ophthalmology Times
In this segment, the panel compares the pivotal QUASAR trial of aflibercept 8 mg in retinal vein occlusion (RVO) with the BALATON and COMINO trials evaluating faricimab. They note that all three studies demonstrated robust visual and anatomic improvements—typically gains…
FDA approvals in 2025: What changed and why it matters for ophthalmologists | Ophthalmology Times
Editor’s Note: This content was generated with the assistance of AI. From first-in-class pharmacologic therapies to next-generation retinal durability strategies and less invasive surgical platforms, 2025 emerged as a pivotal year for the ophthalmic pipeline. Over the past 12 months,…
PRIMAvera study: Central vision improvement with subretinal implant | Ophthalmology Times
The implant is shown placed subretinally in an eye with geographic atrophy due to age-related macular degeneration. (Image courtesy of Frank G. Holz, MD, FEBO, FARVO) (PRIMA) system implant restored central vision and led to a significant improvement in visual…
Refractory dry eye care: How systemic conditions change the game | Ophthalmology Times
Sezen Karakus, MD, discusses strategies for managing refractory dry eye in patients with systemic conditions, highlighting diagnosis, systemic coordination, and emerging treatment options. (Image credit: AdobeStock/Антон Сальников) Refractory dry eye in patients with systemic comorbidities can be challenging to manage…
The year in optometry: 10 stories that defined eye care in 2025 | Ophthalmology Times
(Image Credit: AdobeStock) The past year marked a pivotal period for optometry, with 2025 delivering meaningful clinical, regulatory, and legislative developments that reshaped eyecare practice. Innovation remained front and center as the US FDA authorized Essilor’s Stellest lenses for myopia…
Molecular insights and clinical experience: Extending anti-VEGF durability | Ophthalmology Times
(Image Credit: AdobeStock) A recent Ophthalmology Times Case-Based Roundtable focused on extended anti-VEGF treatment durability. Peter K. Kaiser, MD, the Chaney Family Endowed Chair in Ophthalmology Research and professor of ophthalmology at the Cleveland Clinic Lerner College of Medicine in…
Glaucoma 2026: Which emerging technologies will change practice? | Ophthalmology Times
In this latest EyePod podcast episode, Joel Schuman, MD, of Wills Eye Hospital in Philadelphia, sits down with Sheryl Stevenson, executive editor with the Eye Care Network, to discuss emerging technologies that may influence glaucoma practice as clinicians look to…
Adopting Emerging Therapies in Dry Eye Care | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
How AI is reshaping ophthalmology in 2025 and beyond | Ophthalmology Times
(Image Credit: AdobeStock/ImageFlow) Artificial intelligence (AI) continues to evolve with improved diagnostic abilities, individualized patient treatments, and enhanced surgical accuracy. Some key developments include the analysis of retinal scans that provide earlier disease detection and the ability to spot tumors…